Compare DexCom, Inc. (DXCM) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Snap On Incorporated — how do they compare? DexCom, Inc. trades at $77.82 (market cap $28.06B), while Snap On Incorporated trades at $409.96 (market cap $20.91B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Snap On Incorporated pays a 2.42% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SNA | |
|---|---|---|
Market Cap | $28.06B | $20.91B |
Sector | Health | Technology |
52-Week High | $89.53 | $413.62 |
52-Week Low | $54.84 | $313.01 |
Enterprise Value | $27.03B | $20.43B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
SNA trades at $411.07, up 1.59% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $407.50. Recent Q1 2026 earnings missed estimates, but revenue grew 5.8% year-over-year, and the company maintains strong profitability with a 19.6% net income margin. Strategic acquisitions like Diesel Laptops for $100 million (Business Wire, June 9, 2026) aim to expand heavy-duty diagnostics capabilities.
The stock offers steady dividend income and share repurchases but faces risks from muted growth projections and margin pressures. Analyst sentiment is predominantly bullish (64.7% buy ratings), though valuation at a P/E of 20.84 may limit upside if earnings growth disappoints. Key catalysts include Q2 2026 results on July 23, 2026, with investors watching for organic sales momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
